Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Richard Blake

Physician Assistant, Medical Wasilla, AK Physician Assistant

NPI 1740235829 CMS profile 10935406

3600 E Wickersham Way, Wasilla, AK 99654

Open in the dashboard

General payments

$19,482

953 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Blake of Wasilla, AK is reported in the CMS Open Payments database as having received $19,482 across 953 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,463 139
2024 General $3,408 167
2023 General $4,140 201
2022 General $3,878 210
2021 General $4,593 236

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Blake
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Richard Blake were reported at $3,463. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Richard Blake Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $4,593 $156 $41–$563 $132
2022 $3,878 $185 $55–$649 $149
2023 $4,140 $199 $58–$717 $160
2024 $3,408 $206 $62–$740 $164
2025 $3,463 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,960 189 payments
  2. AstraZeneca Pharmaceuticals LP $2,855 107 payments
  3. Novo Nordisk Inc $1,963 105 payments
  4. GlaxoSmithKline, LLC. $1,931 95 payments
  5. Amgen Inc. $1,118 46 payments
  6. Lilly USA, LLC $926 50 payments
  7. Astellas Pharma US Inc $813 39 payments
  8. Novartis Pharmaceuticals Corporation $765 38 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $705 81 payments
  10. ITI, Inc. $464 16 payments
  11. Other $3,981 187 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $19,343 949 payments
  2. Education $139 4 payments
Products named General payments · program years 2021–2025
  1. BREZTRI $1,398 52 payments
  2. UBRELVY $1,382 59 payments
  3. VRAYLAR $1,296 41 payments
  4. FARXIGA $1,129 33 payments
  5. EVENITY $986 34 payments
  6. NUCALA $884 39 payments
  7. TRULANCE $651 74 payments
  8. Wegovy $611 35 payments
  9. Prolia $559 25 payments
  10. AIRSUPRA $557 17 payments
  11. Other $13,802 744 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 167 drugs

Part D claims

9,123

Median for Physician Assistant: 241

Drug cost

$2,736,073

Median for Physician Assistant: $4,110

Branded share of claims

32.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 233 $345,781
Farxiga Dapagliflozin Propanediol Brand 192 $244,339
Ozempic Semaglutide Brand 151 $226,717
Eliquis Apixaban Brand 150 $188,776
Prolastin C Alpha-1-Proteinase Inhibitor Brand 12 $171,310
Cosentyx Sensoready (2 Pens) Secukinumab Brand 16 $137,017
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 81 $118,523
Repatha Sureclick Evolocumab Brand 79 $101,865
Tresiba Flextouch U-200 Insulin Degludec Brand 95 $100,202
Myrbetriq Mirabegron Brand 91 $90,416

The 10 drugs with the highest cost, of 167 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$206,137

Of which drugs: $132

Medicare patients

509

Average age 73

Services billed

2,500

213 women, 296 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 35%
Ischemic heart disease 33%
Chronic kidney disease 28%
Atrial fibrillation 19%
COPD 19%
Depression 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 43 183 $131

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 43 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$479 39 —
UBRELVY
$250 — —
EVENITY
$231 — —
Veozah
$204 — —
BREZTRI
$193 15 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 43 with Patron

Records

953 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Alaska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record